Abstract
Various stem cells have been explored for the purpose of cardiac repair. However, any individual stem cell population has not been considered as the ideal source. Recently, trophoblast stem cells (TSCs), a newly described stem cell type, have demonstrated extensive plasticity. The present study evaluated the therapeutic effect of TSCs transplantation for heart regeneration in a mouse model of myocardial infarction (MI) and made a direct comparison with the most commonly used mesenchymal stem cells (MSCs). Transplantation of TSCs and MSCs led to a remarkably improved cardiac function in contrast with the PBS control, but only the TSCs exhibited the potential of differentiation into cardiomyocytes in vivo. In addition, a significantly high proliferation level of both transplanted stem cells and resident cardiomyocytes was observed in the TSCs group. These findings primary revealed the therapeutic potential of TSCs in transplantation therapy for MI.
Similar content being viewed by others
Introduction
The massive cardiomyocytes loss following myocardial infarction (MI) predisposes to progressive left ventricular remodeling, heart failure, and causes substantial mortality and morbidity1,2,3. Current treatment approaches aim to prevent further injury and block the maladaptive pathways3,4, but not seek to compensate for the lost myocardium, which is critical owing to the limited regenerative potential of adult cardiomyocytes5,6. Therefore, stem cell therapy has emerged as a novel strategy for MI treatment7,8.
Various types of stem cells have been proposed for cardiac cell therapy8,9, such as skeletal myoblasts, mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), and embryonic stem cells (ESCs). Although several publications describe that stem cell therapy facilitates the recovery of cardiac function post-MI7,10, the individual populations of stem cells have limitations that challenge their common usage8,9,11, including poor cardiomyocytes differentiation, severe arrhythmia, and tumor formation. Thus, “which is the optimal stem cell population” remains an open question in this field.
Trophoblast stem cells (TSCs) are a population of stem cells originating from a single layer of blastocysts when the earliest cell differentiation occurs12. During embryonic development, TSCs contribute to the formation of the placenta, which ensures the exchange of nutrients and oxygen between the mother and the fetus13. Accumulating evidence supports that TSCs have extensive plasticity and are capable of differentiating into a variety of cell morphologies, such as primary trophoblast giant cells, spongiotrophoblast, glycogen cells, and pluripotent stem cells14,15,16. Strikingly, Chaudhry et al.17 recently showed that fetal cells selectively homed to injured maternal hearts and differentiated into cardiomyocytes, endothelial cells, and smooth muscle cells, and about 40% of the fetal cells in the maternal heart expressed caudal-related homeobox2 (Cdx2), a typical marker of TSCs. Therefore, TSCs might be promising for myocardium regeneration owing to their excellent homing capacity and differentiation into cardiac lineage cells. Here, we firstly evaluated the feasibility and efficacy of TSCs transplantation for heart regeneration in a mouse model of MI and determined whether TSCs were superior to MSCs.
Results
Characterization of TSCs
TSC lines were isolated from day 3.5 blastocysts of pregnant GFP-transgenic mice14. Passage 2 cells were cultured in fibroblast-conditioned medium (Supplementary Fig. S1). The expression of the TSCs-specific transcription factor, Cdx218, was detected in the established TSCs by immunofluorescent staining (Fig. 1A). Quantitative real-time polymerase chain reaction (qRT-PCR) data also showed that TSCs marker genes15, including Cdx2, Tfap2c, Fgfr2, and Eomes, were highly expressed in cultured cells, whereas Oct4, the ESCs marker was silenced in the cells (Fig. 1B).
MSCs were isolated from the bone marrow of GFP-transgenic mice, and cultured as described previously19. Immunofluorescent staining demonstrated that MSCs were positive for CD90.2 and CD105, and negative for CD31, a marker of endothelial progenitor cells (EPCs), as well as CD45 and CD117, markers of HSCs (Supplementary Fig. S2A). Flow cytometry analysis further confirmed the characteristic immunophenotype of MSCs (Supplementary Fig. S2B).
TSCs transplantation improved cardiac function after MI
After the cell lines had been established in vitro successfully, vehicles (PBS) or cells (5 × 105 MSCs or 5 × 105 TSCs) were administered into the hearts undergoing MI through intramyocardial injection. The cardiac function was evaluated by echocardiography at baseline, as well as 2 and 3 weeks after cell transplantation. We observed significant improvement in the left ventricular ejection fraction (EF) and fractional shortening (FS) and a significant decrease in the end-diastolic left ventricular inner diameter (LVID;d) and end-systolic left ventricular inner diameter (LVID;s) in mice (Fig. 2A–D). However, no significant difference was detected between the TSCs and MSCs groups with respect to all the echocardiography parameters.
Three weeks after cell transplantation, the mice were sacrificed, and histological analysis was performed. The infarct size and wall thickness were determined by hematoxylin and eosin (HE) staining. The infarct size was significantly smaller in hearts receiving TSCs or MSCs compared to the PBS group (Fig. 2E and Supplementary Fig. S3). The thickness of infarcted myocardium (TIM) (Fig. 2F) and a wall thickness of border zone (WTBZ) (Fig. 2G) were also significantly greater in cell-treated hearts than in PBS only. Nevertheless, no significant difference was found between the two types of stem cells.
Tumorigenesis is a primary risk associated with stem cell therapy. Here, we detected tumor tissue in the hearts, livers, and kidneys of two stem cells-treated mice, on HE-stained sections. Interestingly, no tumor formation was observed in the above major organs of mice, with TSCs and MSCs, 3 weeks after injection (Supplementary Fig. S4).
Together, these results showed that transplantation of TSCs or MSCs improved the cardiac function after MI in mice. However, no statistical differences were noted in cardiac function and LV morphometry, when comparing the TSCs and MSCs groups.
TSCs transplantation reduced fibrosis, cell apoptosis, and enhanced angiogenesis after MI
We next evaluated the effect of stem cell transplantation on the remodeling of injured hearts. Masson trichrome staining was performed for interstitial fibrosis in the border zone. At 3 weeks after MI, collagen content within the border zone was reduced in either of the stem cell-treated groups in contrast to the PBS control group (Fig. 2H and Supplementary Fig. S5A).
We measured the capillaries in the infarct zone and the border zone by immunohistochemistry staining of CD31 at 3 weeks. the capillary density was significantly higher in the groups that received TSCs or MSCs than in the control group both in the infarct and border zones (Fig. 2I and Supplementary Fig. S5B).
Cell apoptosis was quantified by TUNEL assay. In the border zone, the percentage of TUNEL-positive cells was markedly reduced in the cell-treated hearts compared to the hearts that received PBS alone. However, the cell apoptosis in the infarct zone of the three groups did not achieve any statistical significance (Fig. 2J and Supplementary Fig. S5C).
TSCs showed an enhanced retention than MSCs after transplantation into injured hearts
Transplanted stem cells were detected in the infarct and border zone 3 weeks after treatment. Since the transplanted cells had been isolated from GFP-transgenic mice, GFP-positive cells were detected in the infarct and border zone by fluorescent microscopy (Fig. 3A). We found that the proportion of cells expressing GFP was higher in the hearts transplanted with TSCs (19.60 ± 1.25% of all cells) than those with MSCs (11.49 ± 0.76% of all cells) (Fig. 3B and Supplementary Table S1).
To investigate the fate of the transplanted cells under pathological conditions after injection, we performed the TUNEL assay to assess apoptosis and the mitotic marker of phosphorylated Histone-H3 (pH3) staining for proliferation assay (Fig. 3C and E). The number of proliferative stem cells was significantly higher in TSCs-treated hearts (7.75 ± 1.17%) than those treated with MSCs (4.40 ± 0.49%) (Fig. 3F and Supplementary Table S2), whereas the apoptosis of transplanted cells was similar between the two groups (6.09 ± 0.72% in TSCs and 6.86 ± 0.95% in MSCs) (Fig. 3D and Supplementary Table S3).
These observations showed that TSCs had a higher retention compared to MSCs after injection in vivo, which may be correlated to higher proliferation.
Transdifferentiation of TSCs after transplantation
A previous study showed that Cdx2-positive TSCs could differentiate into beating cardiomyocytes when cultured with feeder cardiomyocytes in vitro17. Whether TSCs could exhibit the same ability of differentiation in vivo needs to be elucidated. Thus, we observed the colocalization of GFP and the cardiomyocyte-specific marker, α-actinin, by immunofluorescence. We found that GFP colocalized with α-actinin in hearts receiving TSCs, but not MSCs, providing evidence that TSCs committed to cardiomyocytic lineage (Fig. 4A). However, the number of TSCs committed was quite low.
Next, we found that GFP colocalized with the endothelial cell surface marker, CD31, indicating that the transplanted cells gave rise to endothelial-like cells in vivo (Fig. 4B). On the other hand, both the TSCs and MSCs seemed to incorporate in the formation of the coronary vasculature as identified by co-staining with a vascular marker (von Willebrand factor, vWF) (Fig. 4C).
TSCs transplantation exhibited increased cell proliferation than MSCs, especially the cardiomyocytes proliferation
Increased cell proliferation could contribute towards improving the heart function. Therefore, we assessed whether transplantation of stem cells promotes cell proliferation in the MI hearts. Ki-67 expression showed that cell proliferation was markedly increased in the TSCs-treated group compared to the other two groups both at infarct and border zones (Fig. 5A and B). Importantly, the difference between TSCs and MSCs treatments was also significant.
The previous study showed that the transplantation of MSCs stimulated endogenous cardiomyocytes turnover, including endogenous CPCs and resident cardiomyocytes20. Here, the immunofluorescence data revealed that the host cardiomyocyte turnover was 2-fold higher in TSCs-treated hearts than MSCs at 3 weeks after therapy, as indicated by the expression of pH3 (1.25 ± 0.26% in MSCs and 2.38 ± 0.33% in TSCs) (Figs. 5C and D, Supplementary Table S4).
Microarray analysis
We found a higher proliferative capacity in both the transplanted TSCs and the resident cardiomyocytes in TSCs-treated hearts than the MSCs. However, the molecular mechanism of this difference remains unclear. We suspected that miRNAs, which are involved in the regulation of a variety of genes and functional processes21, might contribute to the proliferative effect of TSCs. The hearts of the three groups were analyzed by miRNA analysis using Affymetrix GeneChip miRNA 4.0 Array. The fold-change filtering (fold change > 2.0) of the differentially expressed miRNAs revealed that 15 miRNAs were up-regulated and 10 miRNAs were downregulated in the MSCs-treated samples compared to the PBS-treated samples. Nine miRNAs were upregulated and 17 downregulated in the TSCs-treated samples (Supplementary Table S5). The results of a two-way hierarchical clustering of the miRNAs and the tissue samples are presented in the heat map illustration (Figs. 6A and B). To identify the significantly differentially expressed miRNAs, we set up a fold change of >2.0 and a P-value of <0.05 as the threshold for screening. Seven miRNAs in MSCs group and 5 miRNAs in TSCs group were confirmed by qRT-PCR (Supplementary Table S6). Subsequently, we found that miR-200b-3p expression was significantly lower in TSCs-treated hearts compared to the MSCs-treated hearts (Fig. 6C and D). MiR-200b has been reported to suppress cell proliferation in several cell lines22,23,24,25. Thus, we propose that miRNA-200b-3p may also be involved in the regulation of the proliferative effect of TSCs.
Discussion
The present study, for the first time, evaluates the effect of TSCs on myocardium repair following MI in mice by direct comparison between MSCs and placebo. The main findings are as follows: (1) TSCs transplantation attenuates the unfavorable process of left ventricular remodeling and improves the cardiac contract function; (2) TSCs, but not MSCs, exhibit the property of differentiation into cardiomyocytes; (3) TSCs also differentiate into endothelial cells and participate in the formation of vasculature in vivo; (4) TSCs display a high potential in stimulating the proliferation of transplanted stem cells and resident cardiomyocytes, potentially through the regulation of miRNA-200b-3p.
The stem cell populations of cell-based therapy for MI can be broadly separated into two categories: pluripotent stem cells and adult stem cells8,9. Pluripotent stem cells, which include ESCs and induced pluripotent stem cells (iPSCs), are plagued by their pluripotency, which may lead to a tumor risk. On the other hand, the adult stem cells that include skeletal myoblasts, bone marrow-derived stem cells, MSCs, and EPCs, are limited to use due to the poor capacity of differentiation towards cardiomyocytes. TSCs, a new type of stem cells derived from the trophectoderm of blastocysts, have a moderate potential for differentiation between pluripotent stem cells and adult stem cells and have been clearly characterized to commit to cardiomyocytic and vascular lineages in vitro17, thereby rendering them a potentially promising stem cell population for cardiac repair.
Our in vivo study found that some transplanted TSCs colocalized with a cardiomyocyte-specific marker, α-actinin, and vascular specific markers, CD31, and vWF, indicating that TSCs were also able to commit towards new cardiomyocytes and vascular cells in vivo. Notably, such a beneficial differentiation is extremely rare. Kara et al. demonstrated that a substantial portion of isolated fetal cells differentiated into spontaneously beating cardiomyocytes when co-cultured with neonatal mice cardiomyocytes17. The discrepancy between the in vitro and in vivo data could probably be attributed to the difference of microenvironment in which TSCs grew. The sophisticated environment in ischemic myocardium, including hypoxia, inflammation, and collagen deposition could greatly affect the fate of implanted stem cells3. A variety of strategies, including pharmacological treatment, gene modification, biomaterials engineering, and microRNAs delivery, are being developed to enhance the survival and differentiation of stem cells in vivo; however, these strategies remain to be optimized, and the effect is yet to be determined26,27,28,29.
Despite that the number of cardiomyocytes differentiated from implanted TSCs was low, a significant improvement in the left ventricular contraction function and a decrease in myocardial remodeling was detected following TSCs injection vs. PBS control. These functional benefits might be related to the effect of TSCs on promoting angiogenesis and proliferation, inhibiting collagen deposition, and cell apoptosis. Several studies in recent years have established that stem cell exerted their beneficial effect via cell cross-talk. MiRNAs have been proved as important messenger molecules, participating in a variety of biochemical and cellular activities, including apoptosis, angiogenesis, and proliferation21,30. Here, microarray analysis and qRT–PCR revealed the up- and down-regulation of miRNAs expression in TSCs or MSCs-treated hearts compared to the PBS group. We observed a similar change between TSCs and MSCs, including miRNA-455-5p, miRNA-330-5p, and miRNA-3058-5p, which may have contribute towards same phenotypes on fibrosis, angiogenesis, and apoptosis.
In addition, TSCs exhibited higher pro-proliferative potential of stem cells and host cells as compared to the MSCs. Microarray analysis and qRT-PCR revealed the difference in miRNA-200b-3p between TSCs and MSCs. Recent reports indicated that miRNA-200b is highly correlated with cell proliferation22,24,25. Especially, in cardiac cell lines, Yao et al.31 demonstrated that miR-200b overexpression inhibited the cell growth and downregulated the expression of cyclin D1 and myosin heavy chain (MHC) by regulating the expression of GATA-4.
Importantly, the transplantation of ESCs or iPSCs may result in the formation of teratomas according to the previous studies32,33, and thus, the safety of stem cell therapy in cardiac repair has always been a concern. In the current study, we examined those organs from where the TSCs may travel away, and no tumor was found, which is probably due to the moderate potential compared to ESCs or iPSCs. On the other hand, the time and number of implanted cells were putative influencing factors. The safety of TSCs application may necessitate an in-depth analysis in future.
Despite these encouraging results and the potential application of the TSCs, there are also limitations in this study. First, the differentiation of TSCs in an in vivo environment requires being further enhanced and liberated. Second, the possible paracrine effect of TSCs warrants clear investigation. Lastly, the isolation and culture of TSCs in human remains a challenge, and thus, the clinical application of TSCs seems like a long way.
Methods
Animal care and protocol
The investigations were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996). The protocols were approved by the Ethics Review Board for Animal Studies of Nanjing Drum Tower Hospital.
Experimental animals
Ten-week-old male and female GFP-transgenic C57BL/6 mice were used to prepare the TSCs and MSCs. Ten-week-old C57BL/6 wild-type (WT) male mice were used as the model of myocardial infarction in the present study. All mice were obtained from the Model Animal Research Center of Nanjing University.
Preparation of TSCs and MSCs
TSCs were derived and maintained as described previously14. Briefly, day 3.5 blastocysts were flushed from the uterus of C57BL/6-gfp pregnant mice. The blastocysts were then transferred onto mitomycin C (MMC)-treated ICR mouse embryonic fibroblasts (MEFs) with TSCs medium comprising of RPMI1640 (Gibco, Invitrogen), 20% fetal bovine serum (FBS, Hyclone, Logan), 1 mM sodium pyruvate (Sigma), 100 μM β-mercaptoethanol (Millipore, Temecula), 2 mM L-glutamine (Chemicon), and F4H (25 ng/mL fibroblast growth factor 4 (FGF4), Invitrogen and 1.0 μg/mL heparin, Sigma). After disaggregation at 5–7 days, the culture medium was replaced with 70% FCM (feeder condition medium) + 1.5 × F4H and refreshed every alternate day. At the time of first passage, the medium was changed to 70% FCM + F4H.
The mouse bone marrow-derived MSCs were isolated based on the CFU-F method19. The bone marrow cells were seeded at 1–2 × 107 cells/100 mm culture dish. After 3 h, the cells were washed twice with PBS to eliminate the non-adherent cells; the attached cells were cultured for 14–16 days. The attached colonies consisting of spindle-shaped cells were observed under a microscope. The colony-forming attached cells were passaged once. The cells were cultured in α-MEM supplemented with 20% FBS, 2 mM L-glutamine, 55 μM 2-mercaptoethanol, 100 U/mL penicillin, and 100 μg/mL streptomycin.
All the cells were cultured at 37 °C in a humidified atmosphere at 5% CO2.
Mouse model of MI and cell transplantation
MI was induced in 10-week-old male C57BL/6 mice by permanent ligation of the left anterior descending coronary artery (LAD) as described in the previous studies34. Briefly, the mice were doped with anesthesia (10% chloral hydrate, 0.3 mL/100 g, i.p.) and maintained under artificial ventilation. The chest cavity was opened, and after careful dissection of the pericardium, LAD was permanently ligated using a 7-0 silk suture. This was followed by injection of either TSCs (5 × 105 cells suspended in 20 μL of PBS, n = 20 animals) or MSCs (5 × 105 cells suspended in 20 μL of PBS, n = 20 animals) at 4 different sites along the infarct border zone with final volume of 5 μL with a 31-gauge syringe (Hamilton) at each site. The cells were suspended in PBS for injection. The vehicle animals (n = 14) received PBS (20 μL) injection in a similar manner. Subsequently, the chest and the overlying skin were closed, allowing the animals to recover under aseptic precautions and analgesic medication (Buprenorphine, 0.1 mg/kg s.c.) to reduce the post-operative pain.
MicroRNA microarray assay
Total RNA was isolated from frozen tissues using the TRIzol reagent (Life Technologies, USA), according to the manufacturer’s protocol. NanoDrop 2000 spectrophotometer (Thermo) and Bioanalyzer 2100 (Agilent) were used to determine the quality and quantity of total RNA.
Microarray assays were performed on Affymetrix GeneChip miRNA 4.0 Array, which contains 3164 mouse miRNA probe sets. The dataset was imported to Microsoft Excel. After normalizing the signal of each microRNA, the expression level was computed, and Student’s t-test was performed to estimate the between-group differences.
Statistical analysis
Quantitative data are expressed as mean ± standard deviation (SD). Paired data were evaluated by Student’s t-test. Multiple comparisons were performed by one-way ANOVA with the Bonferroni post hoc test (SPSS 16.0). P-values < 0.05 were considered to be statistically significant.
Additional Information
How to cite this article: Li, G. et al. Cardiac repair in a mouse model of acute myocardial infarction with trophoblast stem cells. Sci. Rep. 7, 44376; doi: 10.1038/srep44376 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Gheorghiade, M. & Bonow, R. O. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97, 282–289 (1998).
Li, J. et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet (London, England) 385, 441–451, doi: 10.1016/s0140-6736(14)60921-1 (2015).
Sutton, M. G. & Sharpe, N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101, 2981–2988 (2000).
Velagaleti, R. S. et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 118, 2057–2062, doi: 10.1161/circulationaha.108.784215 (2008).
Bergmann, O. et al. Evidence for Cardiomyocyte Renewal in Humans. Science 324, 98–102, doi: DOI 10.1126/science.1164680 (2009).
Ali, S. R. et al. Existing cardiomyocytes generate cardiomyocytes at a low rate after birth in mice. P Natl Acad Sci USA 111, 8850–8855, doi: 10.1073/pnas.1408233111 (2014).
Nguyen, P. K., Riegler, J. & Wu, J. C. Stem cell imaging: from bench to bedside. Cell Stem Cell 14, 431–444, doi: 10.1016/j.stem.2014.03.009 (2014).
Laflamme, M. A. & Murry, C. E. Heart regeneration. Nature 473, 326–335, doi: 10.1038/nature10147 (2011).
Segers, V. F. & Lee, R. T. Stem-cell therapy for cardiac disease. Nature 451, 937–942, doi: 10.1038/nature06800 (2008).
Garbern, J. C. & Lee, R. T. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 12, 689–698, doi: 10.1016/j.stem.2013.05.008 (2013).
Mohsin, S., Siddiqi, S., Collins, B. & Sussman, M. A. Empowering adult stem cells for myocardial regeneration. Circulation research 109, 1415–1428, doi: 10.1161/CIRCRESAHA.111.243071 (2011).
Roberts, R. M. & Fisher, S. J. Trophoblast stem cells. Biology of reproduction 84, 412–421, doi: 10.1095/biolreprod.110.088724 (2011).
Prudhomme, J. & Morey, C. Epigenesis and plasticity of mouse trophoblast stem cells. Cellular and molecular life sciences: CMLS 73, 757–774, doi: 10.1007/s00018-015-2086-9 (2016).
Wu, T. et al. Reprogramming of Trophoblast Stem Cells into Pluripotent Stem Cells by Oct4. Stem Cells 29, 755–763, doi: 10.1002/stem.617 (2011).
Kubaczka, C. et al. Derivation and maintenance of murine trophoblast stem cells under defined conditions. Stem cell reports 2, 232–242, doi: 10.1016/j.stemcr.2013.12.013 (2014).
Red-Horse, K. et al. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. The Journal of clinical investigation 114, 744–754, doi: 10.1172/JCI22991 (2004).
Kara, R. J. et al. Fetal cells traffic to injured maternal myocardium and undergo cardiac differentiation. Circulation research 110, 82–93, doi: 10.1161/CIRCRESAHA.111.249037 (2012).
Strumpf, D. et al. Cdx2 is required for correct cell fate specification and differentiation of trophectoderm in the mouse blastocyst. Development 132, 2093–2102, doi: Doi 10.1242/Dev.01801 (2005).
Mu, D. et al. Intracoronary Transplantation of Mesenchymal Stem Cells with Overexpressed Integrin-Linked Kinase Improves Cardiac Function in Porcine Myocardial Infarction. Scientific reports 6, 19155, doi: 10.1038/srep19155 (2016).
Loffredo, F. S., Steinhauser, M. L., Gannon, J. & Lee, R. T. Bone Marrow-Derived Cell Therapy Stimulates Endogenous Cardiomyocyte Progenitors and Promotes Cardiac Repair. Cell Stem Cell 8, 389–398, doi: DOI 10.1016/j.stem.2011.02.002 (2011).
Gnecchi, M., Pisano, F. & Bariani, R. microRNA and Cardiac Regeneration. Advances in experimental medicine and biology 887, 119–141, doi: 10.1007/978-3-319-22380-3_7 (2015).
Yu, J. et al. miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1. Oncology reports 31, 910–918, doi: 10.3892/or.2013.2897 (2014).
Kim, Y. et al. miR-200b and cancer/testis antigen CAGE form a feedback loop to regulate the invasion and tumorigenic and angiogenic responses of a cancer cell line to microtubule-targeting drugs. The Journal of biological chemistry 288, 36502–36518, doi: 10.1074/jbc.M113.502047 (2013).
Li, P., He, Q. Y. & Luo, C. Q. Overexpression of miR-200b inhibits the cell proliferation and promotes apoptosis of human hypertrophic scar fibroblasts in vitro . The Journal of dermatology 41, 903–911, doi: 10.1111/1346-8138.12600 (2014).
Li, X. Y. et al. MicroRNA-200b inhibits the proliferation of hepatocellular carcinoma by targeting DNA methyltransferase 3a. Molecular medicine reports 13, 3929–3935, doi: 10.3892/mmr.2016.4995 (2016).
Segers, V. F. & Lee, R. T. Biomaterials to enhance stem cell function in the heart. Circulation research 109, 910–922, doi: 10.1161/CIRCRESAHA.111.249052 (2011).
Chen, X. Q. et al. Stem cells with FGF4-bFGF fused gene enhances the expression of bFGF and improves myocardial repair in rats. Biochemical and biophysical research communications 447, 145–151, doi: 10.1016/j.bbrc.2014.03.131 (2014).
Jay, S. M. & Lee, R. T. Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair. Circulation research 113, 933–943, doi: 10.1161/CIRCRESAHA.113.300215 (2013).
Yang, Y. J. et al. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arteriosclerosis, thrombosis, and vascular biology 29, 2076–2082, doi: 10.1161/atvbaha.109.189662 (2009).
Seeger, F. H., Zeiher, A. M. & Dimmeler, S. MicroRNAs in stem cell function and regenerative therapy of the heart. Arteriosclerosis, thrombosis, and vascular biology 33, 1739–1746, doi: 10.1161/ATVBAHA.113.300138 (2013).
Yao, C. X. et al. miR-200b targets GATA-4 during cell growth and differentiation. RNA biology 10, 465–480, doi: 10.4161/rna.24370 (2013).
Nussbaum, J. et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 21, 1345–1357, doi: 10.1096/fj.06-6769com (2007).
Campbell, K. A., Terzic, A. & Nelson, T. J. Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery. Regenerative medicine 10, 773–783, doi: 10.2217/rme.15.41 (2015).
Li, Q. et al. Overexpression of microRNA-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction. Journal of cellular and molecular medicine 18, 919–928, doi: 10.1111/jcmm.12242 (2014).
Acknowledgements
This study was supported by grants from the Natural Science Foundation of China (81200148, 81270281, and 81200092), Jiangsu Provincial Special Program of Medical Science (BL2012014), the Peak of Six Personnel in Jiangsu Province (2013-WSN-008), Funds for Distinguished Young Scientists in Nanjing (JQX13006), and the Key Program of Science Foundation in Nanjing (ZKX13023).
Author information
Authors and Affiliations
Contributions
G.L., J.X., and B.X. conceived and supervised the study and wrote the manuscript. G.L., J.C., X.Z., G.H., W.T., H.W., R.L., Y.C., and R.G. contributed to the experiments and data analysis. All authors discussed the results and approved the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Li, G., Chen, J., Zhang, X. et al. Cardiac repair in a mouse model of acute myocardial infarction with trophoblast stem cells. Sci Rep 7, 44376 (2017). https://doi.org/10.1038/srep44376
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep44376
This article is cited by
-
Trophoblast Stem-Cell-Derived Exosomes Alleviate Cardiotoxicity of Doxorubicin via Improving Mfn2-Mediated Mitochondrial Fusion
Cardiovascular Toxicology (2023)
-
Intratracheal transplantation of trophoblast stem cells attenuates acute lung injury in mice
Stem Cell Research & Therapy (2021)
-
Human trophoblast-derived exosomes attenuate doxorubicin-induced cardiac injury by regulating miR-200b and downstream Zeb1
Journal of Nanobiotechnology (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.